Posts by author
Janet Fricker
Study challenges dogma that RCC is biologically radioresistant
Stereotactic body radiation therapy (SBRT) represents a safe and effective non-invasive treatment for oligometastatic renal cell carcinoma (RCC). The study, published in Lancet Oncology, supports sequential radiotherapy as an alternative treatment option to systemic therapy for oligometastatic renal cell carcinoma.…
Systematic review fills knowledge gaps about metastatic breast cancer
In breast cancer the risk of metastasis is higher among women diagnosed at a younger age, those with larger tumours at diagnosis and those with luminal B breast cancer. The study, abstract 0R-91, presented at the Advanced Breast Cancer Sixth International…
Atlas provides ‘one-stop shop’ for myeloma care information across Europe
Myeloma Patients Europe (MPE) has launched an overview of myeloma and AL amyloidosis treatment inequalities across Europe. The Myeloma Access Atlas, released 19 October, is a platform which has been developed to provide a ‘one-stop’ shop mapping national availability of…
What’s new in lung and colorectal cancer? reports from ESMO 2021
New research findings presented at ESMO 2021 show progress in adjuvant treatment for non-small-cell lung cancer (NSCLC), a novel inhibitor for HER2+ NSCLC patients, and the latest from the FOCUS 4 adaptive, molecularly stratified, umbrella trial platform, set up to…
Dexamethasone helps cancer patients with non-immunogenic tumours survive longer after surgery
Patients with non-immunogenic cancers, such as breast and gynaecological cancers, who are given the anti-nausea drug dexamethasone during surgery survive longer. The study, abstract 4224, presented at the Anesthesiology 2021 annual meeting, held October 8 to 12, San Diego, found…
What’s new in supportive care? presentations from ESMO 2021
Supportive care studies presented at ESMO Congress 2021 highlight the urgent need for survivors to get more support to tackle long-term symptoms and for doctors and patients to get up to date information in a fast-changing oncology landscape. The need…
Round-up of prostate and breast cancer studies from ESMO 2021
The 2021 Congress of the European Society for Medical Oncology (ESMO), held 16‒21 September, featured studies that are likely to impact a broad spectrum of clinical practice. We summarise some of the findings that could change treatments for two of…
Cancer World Editor heads new AACR cancer prevention working group
Adriana Albini, Editor in Chief of Cancer World, has been appointed Chair of the new Cancer Prevention Working Group (CPWG) of the American Association for Cancer Research (AACR). “I’m so happy and honoured to have this responsibility, and with the…
Low risk prostate cancer: real-world data reveals high rates of switching from surveillance to treatment
Over half of men initially managed with active surveillance (AS) for ‘low risk’ prostate cancer switch within four years to definitive treatments (e.g., surgery or radiation therapy). The Canadian study, published in Urology, (20 August) provides real-world data on uptake…
Blood pressure drugs improve survival in colorectal cancer
Common Blood pressure drugs may improve survival in colorectal cancer (CRC). The study, published in Cancer Medicine, (August issue), showed use of Angiotensin Converting Enzyme (ACE) inhibitors, beta blockers and thiazide diuretics were all associated with decreased cancer specific mortality.…